Global Progression Rates of Precursor Lesions for Gastric Cancer: A Systematic Review and Meta-Analysis.

Autor:	Hahn AI; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: hahna1@mskcc.org., Mülder DT; Department of Public Health, Erasmus Medical Center, Rotterdam, the Netherlands., Huang RJ; Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California., Zhou MJ; Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California., Blake B; Weill Cornell Medical College of Cornell University, New York, New York., Omofuma O; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland., Murphy JD; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland., Gutiérrez-Torres DS; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland., Zauber AG; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., O'Mahony JF; Department of Public Health, Erasmus Medical Center, Rotterdam, the Netherlands; School of Economics, University College Dublin, Dublin, Ireland., Camargo MC; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland., Ladabaum U; Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California., Yeh JM; Department of Pediatrics, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts., Hur C; Division of General Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, New York; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York., Lansdorp-Vogelaar I; Department of Public Health, Erasmus Medical Center, Rotterdam, the Netherlands., Meester R; Department of Public Health, Erasmus Medical Center, Rotterdam, the Netherlands; Health Economics & Outcomes Research, Freenome Holdings Inc, San Francisco, California., Laszkowska M; Gastroenterology, Hepatology, and Nutrition Service, Department of Subspecialty Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Jazyk:	angličtina
Zdroj:	Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2024 Oct 01. Date of Electronic Publication: 2024 Oct 01.
DOI:	10.1016/j.cgh.2024.09.003
Abstrakt:	Background & Aims: Whether gastric cancer (GC) precursor lesions progress to invasive cancer at similar rates globally remains unknown. We conducted a systematic review and meta-analysis to determine the progression of precursor lesions to GC in countries with low versus medium/high incidence. Methods: We searched relevant databases for studies reporting the progression of endoscopically confirmed precursor lesions to GC. Studies were stratified by low (<6 per 100,000) or medium/high (≥6 per 100,000) GC incidence countries. Random-effects models were used to estimate the progression rates of atrophic gastritis (AG), intestinal metaplasia (IM), and dysplasia to GC per 1000 person-years. Results: Among the 5829 studies identified, 44 met our inclusion criteria. The global pooled estimates of the progression rate per 1000 person-years were 2.09 (95% confidence interval, 1.46-2.99), 2.89 (2.03-4.11), and 10.09 (5.23-19.49) for AG, IM, and dysplasia, respectively. The estimated progression rates per 1000 person-years for low versus medium/high GC incidence countries, respectively, were 0.97 (0.86-1.10) versus 2.47 (1.70-2.99) for AG (P < .01), 2.37 (1.43-3.92) versus 3.47 (2.13-5.65) for IM (P = .29), and 5.51 (2.92-10.39) versus 14.80 (5.87-37.28) for dysplasia (P = .08). There were no differences for progression of AG between groups when high-quality studies were compared. Conclusions: Similar progression rates of IM and dysplasia were observed among low and medium/high GC incidence countries. This suggests that the potential benefits of surveillance for these lesions in low-risk regions may be comparable with those of population-wide interventions in high-risk regions. Further prospective studies are needed to confirm these findings and inform global screening and surveillance guidelines. (Copyright © 2024 AGA Institute. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu